home / stock / agnpf / agnpf articles

AGNPF Articles, Algernon Pharmaceuticals Inc - Class A - From 07/11/24

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...
Algernon Pharmaceuticals Announces Private Placement | Benzinga

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSW...
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024 | Benzinga

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKF...

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 | Benzinga

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFUR...

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position | Benzinga

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFUR...
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD | Benzinga

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT...

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis | Benzinga

VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFUR...

Algernon Pharmaceuticals Announces Closing of Private Placement | Benzinga

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) (the "Co...
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD | Benzinga

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT:...

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position | Benzinga

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT...

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast | Benzinga

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT...
Previous 10 Next 10